SEC Form 4 · accession 0001209191-17-052022
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darin Lippoldt
Officer — Chief Legal Officer
Period of report
Sep 6, 2017
Accepted (ET)
Sep 8, 2017 · 2:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 6, 2017 | M | 100 | $18.15 | A | 13,257 | D | |
| Common Stock | Sep 6, 2017 | S | 100 | $60.00 | D | 13,157 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF2 | $18.15 | Sep 6, 2017 | M | 100 | D | Nov 3, 2015 | Nov 3, 2024 | Common Stock | 100 | 56,139 | D |
Explanation of responses
- F1The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2Represents option which vested 1/4 upon anniversary of grant (11/3/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018.